Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Exploring the effects of a brief therapy program on suicidal behavior and thoughts

Official title: Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy ASSIP on Neuropsychological Correlates and Psychological Process Factors (NePsyASSIP HT) - Project 2

Run by University of Bern · NCT06263712 · Data updated 2026-11-12

This study is testing a brief therapy program to see if it can help people who have tried to commit suicide feel better compared to those who just get standard care.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment156 (estimated)
SponsorUniversity of Bern
Academic / other
Locations1 site (Bern)
StatusRecruiting
StartedMarch 25, 2024
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedJanuary 22, 2026
Trial IDNCT06263712 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a history of at least one suicide attempt.

Probably not a fit

Patients with serious cognitive impairments or psychotic disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the psychological patterns that differentiate individuals who have attempted suicide from those who only have suicidal thoughts. Participants with a history of suicide attempts will be randomly assigned to receive either the Attempted Suicide Short Intervention Program (ASSIP) or standard care plus a resource interview. The study aims to assess the effectiveness of ASSIP in modulating neuropsychological factors associated with suicidal behavior. Conducted at the University Hospital of Psychiatry and Psychotherapy in Bern, Switzerland, the research will also evaluate the feasibility of home treatment through this intervention.

Why it matters

Potential benefit: If successful, this study could lead to improved therapeutic approaches for individuals at risk of suicide.

How similar studies have gone: Previous studies have shown that brief interventions like ASSIP can be effective, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria for Project 2:

Subjects fulfilling the following inclusion criteria are eligible for the study:

* Informed consent as documented by signature
* Age ≥ 18 years
* At least one previous suicide attempt
* Willingness to attend the ASSIP brief therapy
* Owns a smartphone

Exclusion Criteria for Project 2:

The presence of any one of the following exclusion criteria will lead to exclusion of the subject:

* Serious cognitive impairment
* Any psychotic disorder
* Any current medication, which substantially impairs the attention span, reaction, rate or any other relevant cognitive functions
* Inability to follow the procedures of the study (e.g., insufficient mastery of the German language, previous enrolment into the current study)

Where it's running

  • University Hospital of Psychiatry and Psychotherapy, University of Bern
    Bern, Switzerland
    Recruiting

Study contacts

  • Principal investigator: Anja C. Gysin-Maillart, PhD — University of Bern, University Hospital of Psychiatry, Translational Research Center
  • Study coordinator: Anja C. Gysin-Maillart, PhD
  • Email: anja.gysin-maillart@unibe.ch
  • Phone: +41 (0) 31 632 88 11

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.